On September 8, BIOCYTOGEN-B rose 5.17% in regular trading, trading at HK$61.0/share, with turnover of approximately HK$63.43 million.

On the news front, the company is scheduled to hold its half-year results briefing on September 9, drawing heightened market attention to its business outlook. Additionally, BIOCYTOGEN-B recently announced a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human nanobody molecule derived from its RenNano platform, targeting applications in the neurology therapeutic area. Under the agreement, Qilu Pharma may leverage the licensed nanobody for further R&D exploration in innovative neurological drug development.

The company's interim results released on August 27 showed H1 revenue of RMB 941 million, up 51.6% year-on-year, while net profit attributable to shareholders surged 402.3% to RMB 241 million, marking five consecutive quarters of profitability. The preclinical segment generated RMB 723 million in revenue, up 57.9%, with innovative animal model sales reaching RMB 446 million (+62.4%) at a gross margin of 82.3%. The antibody discovery business posted RMB 218 million in revenue (+33.8%) with a gross margin of approximately 92.8%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)